Related Experiment Video

Updated: Aug 11, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

alpha-Tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2

Chung-Wai Shiau1, Jui-Wen Huang, Da-Sheng Wang

  • 1Division of Medicinal Chemistry, College of Pharmacy, Ohio State University, Columbus, Ohio 43210.

The Journal of Biological Chemistry
|March 8, 2006
PubMed

Insights

Alpha-tocopheryl succinate induces apoptosis in prostate cancer cells by inhibiting Bcl-xL/Bcl-2 function. This mechanism involves disrupting Bak peptide binding, leading to caspase-dependent cell death and offering a basis for developing new cancer therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Alpha-tocopheryl succinate (vitamin E succinate) exhibits antitumor effects, but its mechanism of action is not fully understood.
  • Prostate cancer remains a significant health concern, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To elucidate the mechanism by which alpha-tocopheryl succinate induces apoptosis in prostate cancer cells.
  • To investigate the role of Bcl-xL/Bcl-2 protein interactions in alpha-tocopheryl succinate-mediated cell death.
  • To provide a basis for developing novel Bcl-xL/Bcl-2 inhibitors.

Main Methods:

  • In vitro assays to assess the disruption of Bak BH3 peptide binding to Bcl-xL and Bcl-2.
  • Treatment of prostate cancer cell lines (PC-3 and LNCaP) with alpha-tocopheryl succinate.
  • Caspase activity assays and Western blotting to evaluate apoptosis induction.
  • Molecular docking and structure-activity relationship analysis of alpha-tocopheryl succinate and its derivatives.

Main Results:

  • Alpha-tocopheryl succinate inhibited the binding of Bak BH3 peptide to Bcl-xL and Bcl-2 with an IC50 of 26 microm.
  • Treatment reduced the association of Bcl-2 and Bcl-xL with Bak in PC-3 cells, triggering caspase-dependent apoptosis.
  • Overexpression of Bcl-xL conferred resistance to apoptosis in LNCaP cells, confirming its role in the mechanism.
  • Molecular modeling suggested a hairpin conformation for alpha-tocopheryl succinate, with specific structural features crucial for binding.

Conclusions:

  • Inhibition of Bcl-xL/Bcl-2 function is a key mechanism for alpha-tocopheryl succinate-induced apoptosis in prostate cancer.
  • Structural modifications, particularly truncation of the side chain, can enhance the binding affinity and potency of alpha-tocopheryl succinate derivatives.
  • These findings pave the way for the development of targeted therapies against prostate cancer by inhibiting Bcl-xL/Bcl-2.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...